GSK dou­bles down on vac­cines, HIV meds as CEO Em­ma Walm­s­ley touts 'land­mark' 2022

The step change that Em­ma Walm­s­ley promised at GSK is here, and the CEO has fi­nan­cial re­sults that sur­passed fore­casts to show for it.

GSK re­port­ed Q4 sales of near­ly £7.4 bil­lion, bring­ing full year 2022 sales to £29.3 bil­lion — which the British drug­mak­er said marks a 13% growth at con­stant ex­change rates. Record sales for Shin­grix, GSK’s shin­gles vac­cines, con­tributed a sig­nif­i­cant part of the growth.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN